- Home
- HAFC vs TRVI Comparison
HAFC vs TRVI Comparison
Compare HAFC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFC
- TRVI
- Stock Information
- Founded
- HAFC 1982
- TRVI 2011
- Country
- HAFC United States
- TRVI United States
- Employees
- HAFC N/A
- TRVI N/A
- Industry
- HAFC Major Banks
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- HAFC Finance
- TRVI Health Care
- Exchange
- HAFC Nasdaq
- TRVI Nasdaq
- Market Cap
- HAFC 720.0M
- TRVI 725.7M
- IPO Year
- HAFC 1996
- TRVI 2019
- Fundamental
- Price
- HAFC $26.52
- TRVI $5.95
- Analyst Decision
- HAFC Buy
- TRVI Strong Buy
- Analyst Count
- HAFC 6
- TRVI 9
- Target Price
- HAFC $25.75
- TRVI $19.94
- AVG Volume (30 Days)
- HAFC 157.0K
- TRVI 1.8M
- Earning Date
- HAFC 07-22-2025
- TRVI 08-07-2025
- Dividend Yield
- HAFC 4.07%
- TRVI N/A
- EPS Growth
- HAFC N/A
- TRVI N/A
- EPS
- HAFC 2.13
- TRVI N/A
- Revenue
- HAFC $231,876,000.00
- TRVI N/A
- Revenue This Year
- HAFC $17.80
- TRVI N/A
- Revenue Next Year
- HAFC $7.22
- TRVI N/A
- P/E Ratio
- HAFC $12.45
- TRVI N/A
- Revenue Growth
- HAFC N/A
- TRVI N/A
- 52 Week Low
- HAFC $15.74
- TRVI $2.36
- 52 Week High
- HAFC $27.59
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- HAFC 75.44
- TRVI 48.10
- Support Level
- HAFC $24.17
- TRVI $5.41
- Resistance Level
- HAFC $25.08
- TRVI $6.08
- Average True Range (ATR)
- HAFC 0.79
- TRVI 0.31
- MACD
- HAFC 0.32
- TRVI -0.00
- Stochastic Oscillator
- HAFC 100.00
- TRVI 50.23
About HAFC Hanmi Financial Corporation
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.